福莫特罗、舒弗美及孟鲁司特治疗中度支气管哮喘的临床应用及疗效评价  

Clinical application and effect evaluation of formoterol, theophylline and montelukast in the treatment of moderate bronchial asthma

作　　者：王运 

机构地区：[1]河南省驻马店市中心医院,463000

出　　处：《中国实用医刊》2014年第1期11-13,共3页Chinese Journal of Practical Medicine

摘　　要：目的探讨福莫特罗、舒弗关及孟鲁司特治疗中度支气管哮喘的临床疗效及安全性，并对三种治疗方案的治疗费用进行评价。方法选择驻马店市中心医院2011年3月至2013年3月收治的122例中度支气管哮喘患者（排除存在治疗中断或并发心、脑、肾等重要脏器疾病者），在给予布地奈德气雾剂治疗的基础上，分别联合应用富马酸福莫特罗粉吸入剂（福莫特罗组，40例）、茶碱缓释片（舒弗关组，40例）及孟鲁司特钠片（孟鲁司特组，42例）进行治疗，随访6个月后，对三组患者的哮喘控制情况、治疗效果、治疗费用及不良反应情况进行评价及分析。结果孟鲁司特组患者的ACT评分显著高于其他两组（P〈0．05），而福莫特罗组和舒弗美组间的ACT评分比较差异无统计学意义（P〉0．05）。孟鲁司特组患者的总有效率显著高于其他两组（P〈0．05），而福莫特罗组和舒弗美组间的总有效率比较差异无统计学意义（P〉0．05）。舒弗美组患者的临床治疗费用显著低于其他两组（P〈0．05）；而孟鲁司特组治疗费用显著高于福莫特罗组（P〈0．05）。福莫特罗组患者的不良反应率显著高于其余两组（P〈0．05），而舒弗美组患者及孟鲁司特组患者的不良反应率较低，且差异无统计学意义（P〉0．05）。结论中度支气管哮喘患者在应用布地奈德气雾剂治疗的基础上，联合应用孟鲁司特钠片临床疗效最佳，但从不良反应率及治疗费用上来考虑，应首选联合应用茶碱缓释片。Objective To investigate the clinical efficacy and safty of formoterol, theophylline and montelukast in the treatment of moderate bronchial asthma, and evaluate the cost of the three meth- ods. Methods One hundred and twenty-two patients with moderate bronchial asthma in Zhumadian cen- tral hospital form Mar. 2011 to Mar. 2013 were given treatment of formoterol （formoterol group,40 ea- ses）, theophylline （theophylline group,40 cases）, and montelukast（montelukast group, 42 cases） , be- sides budesonide aerosol, all the patients were not complicated with heart, brain, kidney or other organs diseases, no patient interrupt the treatment. All of the patients were followed up for 6 months, asthma control, clinical efficacy, cost and adverse reactions were analyzed. Results ACT scores in montelukast group were higher than those in other groups significantly （P 〈 0. 05）, but in formoterol and theophylline group, there was no significant difference （P 〉 0. 05 ）. The total efficacy in montelukast group was higher than that in other groups significantly （P 〈 0. 05 ）, but in formoterol and theophylline group, there was no significant difference （P 〉 0. 05 ）. The cost in theophylline group was lower than that in other groups sig- aificantly （P 〈 0. 05 ）, it was higher in montelukast group than that in formoterol group significantly（P 〈 ）. 05 ）. Adverse reactions in formoterol group were higher than those in other groups significantly （P 〈 ）. 05 ）, adverse reactions in theophylline and montelukast group had no significant difference （P 〉 ）. 05 ）. Conclusions Montelukast combined with budesonide aerosol treating moderate bronchial asthma 1as the best efficacy, considering the cost and adverse reactions, theophyiline combined with budesonide terosol is preferred.

关 键 词：支气管哮喘 中度 福莫特罗 舒弗美 孟鲁司特 临床疗效 治疗费用 

分 类 号：R562.25[医药卫生—呼吸系统]